10. Roche/Adaptive Biotech by Phil Taylor The deal, focused on TCR therapies, promises Seattle-based Adaptive more than $2 billion in milestone payments if all goes according to plan.
Genentech, Bicycle form discovery-stage immuno-oncology pact by Nick Paul Taylor Tuesday, February 25, 2020 Bicycle will apply its discovery platform to multiple targets, putting itself in a position to pull in up to $1.7 billion in milestones.
Roche posts data on SMA rival to drugs from Biogen, Novartis by Nick Paul Taylor Thursday, February 6, 2020 The update adds figures to Roche’s earlier top-line readout but leaves questions about the competitiveness of risdiplam unanswered.
Roche's risdiplam clears another phase 3 SMA trial by Nick Paul Taylor Thursday, January 23, 2020 The clinical success comes months before the FDA is set to decide whether to approve the survival motor neuron-2 splicing modifier.
Forma Therapeutics nets $100M to push sickle cell treatment by Amirah Al Idrus Thursday, December 19, 2019 Genentech veteran Frank Lee landed at Forma Therapeutics as it aimed to go from an early-stage company to one knocking on the door of approval.
Canaan Partners promotes Julie Grant to general partner by Amirah Al Idrus Thursday, December 12, 2019 Julie Grant is the fourth woman to join Canaan’s ranks of general partners. She joins Maha Ibrahim, Nina Kjellson and Wende Hutton.
Roche bispecific delivers complete responses in tough patients by Nick Paul Taylor Monday, December 9, 2019 A phase 1/2b test showed Roche's antibody mosunetuzumab can trigger durable responses in a significant minority of hard-to-treat NHL patients.
Aridis nabs pharma veteran as ex-CMO leaves after drug flop by Ben Adams Friday, October 11, 2019 Micro cap anti-infective biotech Aridis Pharmaceuticals has gained a new chief medical officer in the form of former Takeda Vaccines exec Paul Mendelm
Gilead nabs Genentech exec as new CMO by Ben Adams Monday, October 7, 2019 After a series of major exits from its C-suite including the exit of Chief Medical Officer Andrew Cheng last fall, Gilead now has a new CMO.
ESMO: Roche, Genentech see success with lung cancer blood tests by Conor Hale Monday, September 30, 2019 With new data exploring lung cancer biomarkers, Roche says that DNA blood tests could soon replace tissue biopsies for picking targeted treatments.
